A Phase 3 interventional study of rhTPO and Placebo in Thrombocytopenia Associated With Chronic Liver Disease, sponsored by MIBIO PTE. LTD.. Recruiting at 2 sites in Georgia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by MIBIO PTE. LTD. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing recombinant human thrombopoietin in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. recombinant human thrombopoietin · Thrombocytopenia.
Among the 18 studies testing recombinant human thrombopoietin in Thrombocytopenia, this one is the 5th largest by planned enrollment, is one of 3 that started in 2026, is one of 4 in phase 3, and was the 17th registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →6 of the 18 studies testing recombinant human thrombopoietin in Thrombocytopenia are open now, in 2 countries. Recruiting first, the newest first:
Anhui Provincial Hospital · Sites in China
Ages 18+
The First Affiliated Hospital of Dalian Medical University · Sites in China
Ages 18–85
Ruilan Wang · Sites in China
Ages 18–85
The First Affiliated Hospital of Zhengzhou University
Ages 18–75
Sun Yat-sen University
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 5 · Phase 4 4
First in 1998; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 70 across the 18 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 18 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with MIBIO PTE. LTD. as lead sponsor.
MIBIO PTE. LTD. has 1 study filed under Thrombocytopenia — fewer than ten, so there is no comparison to draw.
1 of the studies testing recombinant human thrombopoietin in Thrombocytopenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07334093Sun Yat-sen UniversityA Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients. | 2027-11-15 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing recombinant human thrombopoietin in Thrombocytopenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a global, multicenter, randomized, double-blind, placebo-controlled study using recombinant human thrombopoietin stimulating factor ( rhTPO) to treat adults with Chronic liver disease-related thrombocytopenia (CLDT). The study will evaluate rhTPO efficacy in elevating platelet level and its safety in the treatment of thrombocytopenia associated with liver disease prior to an elective procedure to reduce pre-procedural platelet transfusion needs and the requirements for rescue treatment for bleeding.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: rhTPO
For subcutaneous injection once daily, for up to 5 or 7 days
For subcutaneous injection once daily, for up to 5 or 7 days
Proportion of subjects who require no platelet transfusion prior to the elective invasive procedure and no rescue therapy for bleeding.
Time frame: 22 days
Proportion of subjects achieving the target platelet count from Baseline to Procedure Day before any platelet transfusion;
Time frame: 8-15 days
Change in platelet count from Baseline to Pre-Procedural Assessment;
Time frame: 8-14 days
Not enrolling at this site.
Plan to share: No — No this kind of plan currently.
Started Oct 2026 (actual). Primary completion is estimated for Oct 2028, 24 months after the start.
Of 29 phase 3 interventional studies under Thrombocytopenia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 45. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recombinant human thrombopoietin